Rosen; Perry
Patent Applications and Registrations
Patent applications and USPTO patent grants for Rosen; Perry.The latest application filed is for "methylmaleimidyl polymer derivatives".
- Rosen; Perry - North Caldwell NJ
- Rosen; Perry - Seattle WA
| Patent | Date |
|---|---|
| Methylmaleimidyl polymer derivatives App 20070141021 - Rosen; Perry ; et al. | 2007-06-21 |
| Bifunctional polyethylene glycol derivatives Grant 7,217,845 - Rosen , et al. May 15, 2 | 2007-05-15 |
| Monofunctional polyethylene glycol aldehydes Grant 7,041,855 - Rosen , et al. May 9, 2 | 2006-05-09 |
| Monofunctional polyethylene glycol aldehydes Grant 6,956,135 - Rosen , et al. October 18, 2 | 2005-10-18 |
| Monofunctional polyethylene glycol aldehydes Grant 6,916,962 - Rosen , et al. July 12, 2 | 2005-07-12 |
| Novel monofunctional polyethylene glycol aldehydes App 20040147687 - Rosen, Perry ; et al. | 2004-07-29 |
| Novel monofunctional polyethylene glycol aldehydes App 20040122164 - Rosen, Perry ; et al. | 2004-06-24 |
| Bifunctional polyethylene glycol derivatives App 20040115165 - Rosen, Perry ; et al. | 2004-06-17 |
| Novel monofunctional polyethylene glycol aldehydes App 20040034188 - Rosen, Perry ; et al. | 2004-02-19 |
| Novel monofunctional polyethylene glycol aldehydes App 20030153694 - Rosen, Perry ; et al. | 2003-08-14 |
| Polyethylene-protein conjugates Grant 5,849,860 - Hakimi , et al. December 15, 1 | 1998-12-15 |
| Polyethylene-protein conjugates Grant 5,834,594 - Hakimi , et al. November 10, 1 | 1998-11-10 |
| Polyethylene-protein conjugates Grant 5,792,834 - Hakimi , et al. August 11, 1 | 1998-08-11 |
| Polyethylene-protein conjugates Grant 5,747,646 - Hakimi , et al. May 5, 1 | 1998-05-05 |
| Polyethylene-protein conjugates Grant 5,595,732 - Hakini , et al. * January 21, 1 | 1997-01-21 |
| Polyethylene-protein conjugates Grant 5,559,213 - Hakimi , et al. September 24, 1 | 1996-09-24 |
| Polymer for making poly(ethylene glycol)-protein conjugates Grant 5,539,063 - Hakimi , et al. July 23, 1 | 1996-07-23 |
| Compounds useful as dual antagonists of platelet activating factor and leukotriene D.sub.4 Grant 5,428,004 - Earley , et al. June 27, 1 | 1995-06-27 |
| Peg-interferon conjugates Grant 5,382,657 - Karasiewicz , et al. January 17, 1 | 1995-01-17 |
| Unsaturated eicosanoic acids Grant 4,642,364 - Chan , et al. February 10, 1 | 1987-02-10 |
| 16-Fluoro prostaglandins Grant 4,410,720 - Holland , et al. October 18, 1 | 1983-10-18 |
| Process for preparing 2,4-diamino-pyrimidines Grant 4,255,574 - Rosen March 10, 1 | 1981-03-10 |
| 16-Substituted prostaglandins Grant 4,204,074 - Holland , et al. May 20, 1 | 1980-05-20 |
| 16-Substituted prostaglandins Grant 4,187,381 - Holland , et al. February 5, 1 | 1980-02-05 |
| Process for substituted 5-benzyl-2,4-diamino-pyrimidines Grant 4,143,227 - Rosen March 6, 1 | 1979-03-06 |
| 16-CF.sub.3 prostaglandins Grant 4,112,225 - Holland , et al. September 5, 1 | 1978-09-05 |
| Process for preparing substituted 2,4-diaminopyrimidines and isoxazole intermediate Grant 4,075,209 - Jernow , et al. February 21, 1 | 1978-02-21 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 